Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Pharma Holding's Other Operating Expense for the
three
months ended in Mar. 2026 was €-0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.13 Mil.
China Pharma Holding's quarterly Other Operating Expense
declined
from Sep. 2025 (€0.02 Mil) to Dec. 2025 (€-0.02 Mil) but then
increased
from Dec. 2025 (€-0.02 Mil) to Mar. 2026 (€-0.00 Mil).
China Pharma Holding's annual Other Operating Expense
declined
from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€-0.00 Mil) and
declined
from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.13 Mil).
China Pharma Holding Other Operating Expense Related Terms
China Pharma Holding Other Operating Expense Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €-0.13 Mil mean?
China Pharma Holding (STU:XQJ) has a Other Operating Expense of €-0.13 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on China Pharma Holding and its competitors.
Is China Pharma Holding's Other Operating Expense too high?
China Pharma Holding's current Other Operating Expense is €-0.13 Mil. Overall, China Pharma Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Other Operating Expense compare to INCR and TLPH?
China Pharma Holding's Other Operating Expense of €-0.13 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on China Pharma Holding and its competitors. China Pharma Holding's current Other Operating Expense is €-0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current Other Operating Expense of €-0.13 Mil. The stock's GF Value™ is €5.79, compared to a current price of €26.80 — trading 362.9% above its estimated fair value. The current Other Operating Expense is €-0.13 Mil. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current Other Operating Expense is €-0.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 362.9% above its estimated GF Value™ of €5.79.
Key valuation signals for STU:XQJ:
Other Operating Expense: €-0.13 Mil
GF Value™: €5.79 vs. price of €26.80 (362.9% above fair value)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for STU:XQJ
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
